

RESEARCH MONOGRAPH . COMPOUND PROFILE

Ezetimibe

A 2-azetidinone cholesterol absorption inhibitor developed at the Schering-Plough Research Institute, first-in-class for selective blockade of Niemann-Pick C1-Like 1 mediated intestinal sterol uptake, with landmark cardiovascular outcomes evidence from the IMPROVE-IT trial and broad clinical positioning as add-on therapy to statins.

DOCUMENT	KDC-MN-1559
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Selective cholesterol absorption inhibitor targeting Niemann-Pick C1-Like 1 (NPC1L1) transporter protein

ABSTRACT

Ezetimibe is a selective cholesterol absorption inhibitor and the founding member of a pharmacological class that targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein at the brush border membrane of small intestinal enterocytes and on the canalicular membrane of hepatocytes. Developed at the Schering-Plough Research Institute through a medicinal chemistry program that originated in acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor optimization, the compound was identified as SCH 58235 and advanced to regulatory approval by the United States Food and Drug Administration in October 2002 for the treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, homozygous sitosterolemia, and mixed hyperlipidemia. At the standard oral dose of 10 mg once daily, ezetimibe reduces intestinal cholesterol absorption by approximately 54 percent, produces a 15 to 22 percent reduction in low-density lipoprotein cholesterol (LDL-C) as monotherapy, and provides an incremental 23 to 24 percent LDL-C reduction when added to ongoing statin therapy. The molecular mechanism involves direct binding to NPC1L1, a polytopic transmembrane protein with sterol-sensing domains homologous to the Niemann-Pick type C1 protein (NPC1), blocking the clathrin/AP2-mediated endocytosis of the NPC1L1-cholesterol complex and thereby preventing cholesterol translocation from the intestinal lumen into the enterocyte cytoplasm.

The pharmacokinetic profile is dominated by rapid absorption followed by extensive first-pass glucuronidation to the pharmacologically active ezetimibe-glucuronide conjugate, which

constitutes 80 to 90 percent of circulating drug. Both ezetimibe and its glucuronide undergo enterohepatic recirculation, producing a prolonged effective half-life of approximately 22 hours that supports once-daily dosing. Metabolism is mediated principally by uridine 5'-diphosphate-glucuronosyltransferase (UGT) isoenzymes 1A1, 1A3, and 2B15, with minimal cytochrome P450 involvement, conferring a favorable drug-drug interaction profile relative to the statin class. Approximately 78 percent of the administered dose is excreted in feces, predominantly as parent ezetimibe, with the remainder recovered in urine as the glucuronide conjugate.

The clinical evidence base for ezetimibe is anchored by two landmark cardiovascular outcomes trials. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), published in 2015, randomized 18,144 patients with recent acute coronary syndrome to simvastatin plus ezetimibe versus simvastatin plus placebo and demonstrated a statistically significant 6.4 percent relative reduction in the primary composite cardiovascular endpoint (hazard ratio 0.936, $p = 0.016$) at a median follow-up of six years, establishing ezetimibe as the first non-statin lipid-lowering agent to demonstrate incremental cardiovascular benefit when added to statin therapy [1]. The SHARP trial (Study of Heart and Renal Protection) randomized approximately 9,270 patients with chronic kidney disease to simvastatin plus ezetimibe versus placebo and demonstrated significant reduction in major atherosclerotic events [2]. These trials collectively validated the LDL-C hypothesis beyond the statin class and positioned ezetimibe as a standard component of guideline-directed lipid management.

This monograph reviews the chemistry, synthesis, and structural pharmacology of ezetimibe; the NPC1L1 transporter biology and molecular mechanism of action; the comprehensive human pharmacokinetic record; the preclinical efficacy data in atherosclerosis and hypercholesterolemia models; the clinical evidence base across cardiovascular outcomes, chronic kidney disease, and combination therapy; sourcing and quality verification considerations; reconstitution and handling; stack interactions with statins, fibrates, bile acid sequestrants, and PCSK9 inhibitors; adverse events and safety signal including hepatic and musculoskeletal considerations; and a comparative assessment of five alternative non-statin lipid-lowering agents (bempedoic acid, evolocumab, alirocumab, inclisiran, colesevelam) against ezetimibe on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Ezetimibe.

Marketed names: Zetia (Merck/MSD; United States, Canada, and multiple international jurisdictions), Ezetrol (MSD; European Union, United Kingdom, Australia, New Zealand, and other ex-US jurisdictions), Inegy and Vytorin (fixed-dose combinations with simvastatin). Multiple generic formulations are available worldwide following patent expiration in 2017.

Development codes: SCH 58235 (Schering-Plough Research Institute). The development code is the canonical identifier in the discovery chemistry literature and in the seminal Clader (2004) and Rosenblum et al. (1998) publications describing the design and optimization of the azetidinone cholesterol absorption inhibitor series [3, 4].

Chemical Abstracts Service registry number: 163222-33-1 (free base). No salt form is used in commercial formulations; the compound is administered as the free base.

International Union of Pure and Applied Chemistry name: (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one. The compound is a substituted 2-azetidinone (beta-lactam) bearing fluorophenyl, hydroxyphenyl, and hydroxypropyl substituents arranged around the four-membered ring with defined stereochemistry at three chiral centers.

1.2 Structural class and chemistry

Ezetimibe is a 2-azetidinone (beta-lactam) derivative, structurally unrelated to statins, fibrates, bile acid sequestrants, or any other previously developed lipid-lowering class. The azetidinone ring, shared with the beta-lactam antibiotics at a structural level only, provides a rigid scaffold for the spatial arrangement of the

pharmacophoric elements required for NPC1L1 binding. The compound belongs to a series of cholesterol absorption inhibitors developed through iterative optimization from the ACAT inhibitor lead compound SCH 48461 [3].

Molecular formula: C₂₄H₂₁F₂NO₃.

Exact mass: 409.1489 g/mol (monoisotopic).

Molecular weight: 409.43 g/mol.

Physical properties: White to off-white crystalline powder. Practically insoluble in water (aqueous solubility less than 0.01 mg/mL at pH 7.0). Freely soluble in ethanol, methanol, and dimethyl sulfoxide. The compound is formulated as a tablet with standard pharmaceutical excipients to achieve adequate oral bioavailability despite the low aqueous solubility. Melting point is approximately 163 to 166 degrees Celsius.

Stereochemistry: Ezetimibe possesses three stereogenic centers and is supplied as a single enantiomer with the (3R,4S,3'S) configuration. The stereochemistry is essential for pharmacological activity; the enantiomeric series was evaluated during the discovery program, and the (3R,4S,3'S) isomer demonstrated substantially greater cholesterol absorption inhibition than its stereoisomers in preclinical models [4]. Investigators acquiring research-grade ezetimibe should confirm stereochemical purity by chiral high-performance liquid chromatography.

1.3 Synthesis

The published synthesis of ezetimibe proceeds through a convergent route that constructs the azetidinone ring through a [2+2] cycloaddition or Staudinger reaction between an appropriately substituted imine and a ketene equivalent, followed by stereoselective elaboration [3, 4]. The Rosenblum et al. (1998) disclosure described the design rationale: SCH 58235 was engineered from the metabolically labile precursor SCH 48461 by incorporating fluorine atoms at sites of oxidative metabolism to block CYP-mediated inactivation, while simultaneously introducing the 4-hydroxyphenyl group as a pharmacophoric element that would resist conjugation and enhance target binding [4]. Industrial synthesis employs asymmetric methods (chiral auxiliary or enantioselective catalysis) to achieve the required (3R,4S,3'S) configuration with high enantiomeric excess (greater than 99 percent). The product is purified by recrystallization (typically from ethanol or ethyl acetate) and characterized by nuclear magnetic resonance spectroscopy, mass spectrometry, high-per-

formance liquid chromatography, and polarimetry. The manufacturing route has been optimized for cost-efficiency following patent expiration, and multiple generic manufacturers produce the compound at pharmaceutical grade.

2. Abstract

Ezetimibe (SCH 58235) is a first-in-class selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein at the brush border of small intestinal enterocytes and at the canalicular membrane of hepatocytes, preventing the uptake of dietary and biliary cholesterol into the enterocyte cytoplasm [5, 6]. The compound was approved by the United States Food and Drug Administration in October 2002 and is registered in more than 100 jurisdictions worldwide for the treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, homozygous sitosterolemia, and mixed hyperlipidemia, either as monotherapy or in combination with a statin.

At the standard 10 mg once-daily oral dose, ezetimibe reduces LDL-C by approximately 18 percent as monotherapy and provides an incremental 23 to 24 percent reduction when combined with statin therapy, producing total LDL-C reductions of 45 to 60 percent depending on the statin and dose [7, 8]. The mechanism is complementary to statin-mediated inhibition of hepatic cholesterol synthesis: reduction of intestinal cholesterol delivery to the liver triggers compensatory upregulation of hepatic LDL receptor expression, producing additive LDL-C lowering.

The IMPROVE-IT trial (Cannon et al. 2015), a randomized double-blind trial of 18,144 patients with recent acute coronary syndrome followed for a median of six years, demonstrated that the addition of ezetimibe 10 mg to simvastatin 40 mg reduced the primary composite cardiovascular endpoint (cardiovascular death, non-fatal myocardial infarction, unstable angina requiring hospitalization, coronary revascularization occurring 30 or more days after randomization, or non-fatal stroke) from 34.7 percent to 32.7 percent (hazard ratio 0.936, 95 percent confidence interval 0.89 to 0.99, $p = 0.016$) [1]. This result established ezetimibe as the first non-statin therapy to demonstrate incremental cardiovascular outcomes benefit and validated the LDL-C hypothesis for non-statin mechanisms.

The SHARP trial (Baigent et al. 2011) randomized 9,270 patients with chronic kidney disease to simvastatin 20 mg plus ezetimibe 10 mg versus placebo and demonstrated a 17 percent relative reduction in major atherosclerotic events (rate ratio

0.83, 95 percent confidence interval 0.74 to 0.94, $p = 0.0021$), extending the cardiovascular benefit to a population for which statin monotherapy data had been inconsistent [2].

Pharmacokinetics are characterized by rapid oral absorption, extensive first-pass glucuronidation to the active ezetimibe-glucuronide by UGT1A1, UGT1A3, and UGT2B15, enterohepatic recirculation producing a 22-hour effective half-life, and predominantly fecal excretion. The minimal cytochrome P450 involvement confers a favorable drug interaction profile. The compound is well tolerated; the adverse-event profile in controlled trials is similar to placebo when used as monotherapy, with modest incremental risk of hepatic transaminase elevation and myopathy when combined with statins.

This monograph documents chemistry, synthesis, NPC1L1 transporter biology and molecular pharmacology, comprehensive pharmacokinetics, preclinical efficacy in atherosclerosis models, the clinical evidence base across cardiovascular outcomes and combination therapy, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a structured comparative assessment of five non-statin lipid-lowering agents (bempedoic acid, evolocumab, alirocumab, inclisiran, colesevelam) against ezetimibe on five standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

3. Discovery and Development History

3.1 Origin

Ezetimibe emerged from a cholesterol absorption inhibitor program at the Schering-Plough Research Institute in Kenilworth, New Jersey, during the 1990s. The program originated in the optimization of ACAT inhibitors, a class of compounds designed to block intracellular cholesterol esterification. During in vivo testing of ACAT inhibitor leads, Schering-Plough investigators observed that certain azetidinone derivatives inhibited intestinal cholesterol absorption through a mechanism independent of ACAT activity [3]. This observation redirected the medicinal chemistry effort from ACAT inhibition to cholesterol absorption inhibition as the primary pharmacological target.

3.2 Medicinal chemistry optimization

The lead compound in the absorption inhibitor series, SCH 48461, demonstrated potent cholesterol absorption inhibition in cholesterol-fed hamster models but was extensively metabolized by hepatic cytochrome P450 enzymes, limiting its oral bioavailability and pharmacokinetic profile. The Clader laboratory at Schering-Plough conducted a systematic structure-activity relationship campaign in which metabolic soft spots on the SCH 48461 scaffold were identified and blocked through strategic fluorine substitution and hydroxyl group placement [3]. SCH 58235, the compound that became ezetimibe, was the product of this metabolism-guided design: fluorine atoms were placed at positions vulnerable to oxidative metabolism, and the 4-hydroxyphenyl group was incorporated as a pharmacophoric element that enhanced target binding while resisting metabolic conjugation. Rosenblum et al. (1998) published the synthesis and preclinical characterization of SCH 58235, reporting potent, orally active, dose-dependent inhibition of cholesterol absorption in hamsters, rats, and rhesus monkeys [4]. The compound was approximately 400-fold more potent than SCH 48461 in the hamster cholesterol absorption assay.

3.3 Target identification

At the time of initial clinical development, the molecular target of ezetimibe was unknown. The compound was advanced through Phase 1, Phase 2, and Phase 3 clinical trials on the basis of its pharmacological activity (cholesterol absorption inhibition) rather than a defined receptor or transporter target. The target was identified in 2004 when Altmann et al. at Schering-Plough reported that NPC1L1 (Niemann-Pick C1-Like 1), a polytopic transmembrane protein with sterol-sensing domains, was critical for intestinal cholesterol absorption and that NPC1L1 knock-out mice were resistant to the cholesterol-absorbing effects of dietary cholesterol and were phenocopies of ezetimibe-treated animals [5]. Garcia-Calvo et al. (2005) subsequently demonstrated that ezetimibe binds directly to NPC1L1 using photoaffinity labeling and binding displacement studies [6]. This post-approval target identification is unusual in drug development and has been cited as a notable example of successful phenotype-driven drug discovery.

3.4 Clinical development and regulatory approval

Ezetimibe entered Phase 1 clinical trials in the late 1990s. Phase 2 and Phase 3 trials in primary hypercholesterolemia demonstrated consistent LDL-C reduction of approximately 18 percent as monotherapy and approximately 25 percent additive reduction when combined with statins [7, 8]. The FDA approved ezetimibe (Zetia) in October 2002 for primary hypercholesterolemia (as monotherapy and in combination with a statin), homozygous familial hypercholesterolemia (in combination with a statin), and homozygous sitosterolemia. A fixed-dose combination tablet with simvastatin (Vytorin) was approved in July 2004.

3.5 Post-approval cardiovascular outcomes development

Following initial approval on the basis of LDL-C lowering (a surrogate endpoint), the cardiovascular outcomes program was initiated to establish that ezetimibe-mediated LDL-C reduction translated to clinical event reduction. The ENHANCE trial (Kastelein et al. 2008) evaluated ezetimibe/simvastatin versus simvastatin alone on carotid intima-media thickness in familial hypercholesterolemia patients over two years and showed no significant difference in the imaging endpoint despite significant LDL-C reduction, generating controversy about the clinical relevance of ezetimibe [9]. The subsequent IMPROVE-IT trial (Cannon et al. 2015), powered for clinical

cal cardiovascular events, resolved this controversy by demonstrating significant event reduction over six years, establishing the cardiovascular outcomes evidence that now anchors ezetimibe's position in clinical guidelines [1].

3.6 Patent expiration and generic availability

The core patent for ezetimibe expired in 2017 in the United States and in 2018 in the European Union, resulting in widespread generic availability. The compound is now manufactured by multiple generic pharmaceutical companies worldwide, and pricing has decreased substantially from the branded product. The fixed-dose combination with simvastatin (Vytorin/Inegy) also faces generic competition.

4. Mechanism of Action

Ezetimibe is a selective inhibitor of intestinal cholesterol absorption that acts through blockade of the NPC1L1 transporter protein. The mechanism is distinct from all other lipid-lowering drug classes and is complementary to the statin mechanism of hepatic HMG-CoA reductase inhibition.

4.1 NPC1L1 transporter biology

NPC1L1 (Niemann-Pick C1-Like 1) is a 1,332-amino-acid polytopic transmembrane glycoprotein with 13 predicted transmembrane domains and a sterol-sensing domain homologous to that found in the Niemann-Pick type C1 protein (NPC1), the SCAP (SREBP cleavage-activating protein), and HMG-CoA reductase [5, 10]. The protein shares 42 percent amino acid identity with NPC1, a lysosomal cholesterol transport protein whose loss of function causes Niemann-Pick type C disease. NPC1L1 is expressed at high density on the apical (luminal) brush border membrane of jejunal enterocytes and on the canalicular membrane of hepatocytes. In the intestine, NPC1L1 mediates the uptake of micellar cholesterol from the intestinal lumen into the enterocyte; in the liver, NPC1L1 is involved in the reabsorption of cholesterol from bile (relevant primarily in humans, where hepatic NPC1L1 expression is substantial, and less so in mice, where expression is low) [10, 11].

Under physiological conditions, the cholesterol uptake process mediated by NPC1L1 involves several sequential steps. When luminal free cholesterol concentration exceeds a threshold, cholesterol inserts into the plasma membrane and is sensed by the sterol-sensing domain of NPC1L1 localized at the cell surface. NPC1L1 and associated cholesterol are then internalized through clathrin/AP2-mediated endocytosis, transported along microfilaments to the endocytic recycling compartment, and eventually delivered to the endoplasmic reticulum for esterification by ACAT2 and incorporation into chylomicron particles for secretion into lymph [10].

4.2 Ezetimibe binding and inhibition of NPC1L1 internalization

Ezetimibe binds directly to the extracellular sterol-binding domain of NPC1L1. Garcia-Calvo et al. (2005) demonstrated this binding through photoaffinity cross-linking with a tritium-labeled ezetimibe analog, showing saturable, high-affinity binding to NPC1L1 in intestinal brush border membrane preparations that was absent in NPC1L1 knockout tissue [6]. The binding event blocks the interaction between the NPC1L1-cholesterol complex and the clathrin/AP2 endocytic machinery, preventing the internalization step that would otherwise transport cholesterol into the enterocyte cytoplasm [10]. Cholesterol therefore remains in the intestinal lumen and is excreted in feces.

The glucuronide metabolite of ezetimibe (ezetimibe-glucuronide) retains pharmacological activity at NPC1L1, and the enterohepatic recirculation of both parent compound and glucuronide metabolite delivers repeated drug exposure to the intestinal brush border, contributing to the sustained pharmacological effect with once-daily dosing [12].

4.3 Consequences for cholesterol homeostasis

Blockade of intestinal cholesterol absorption by ezetimibe reduces the delivery of cholesterol to the liver via chylomicron remnants. The resulting decrease in hepatic cholesterol content triggers several compensatory homeostatic responses: (a) upregulation of hepatic LDL receptor expression through the SREBP-2 pathway, increasing clearance of circulating LDL particles; (b) upregulation of hepatic cholesterol synthesis through increased HMG-CoA reductase expression; and (c) reduced hepatic VLDL cholesterol content and secretion [13]. The net clinical effect is a 15 to 22 percent reduction in circulating LDL-C. The compensatory increase in hepatic cholesterol synthesis partially offsets the absorption reduction and is the pharmacological rationale for combining ezetimibe with a statin: the statin blocks the compensatory synthesis, and the combination produces additive or supra-additive LDL-C lowering.

4.4 Selectivity

Ezetimibe is highly selective for NPC1L1-mediated cholesterol transport. At pharmacologically relevant concentrations, the compound does not inhibit the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or fat-soluble vitamins (A, D, E, K) in preclinical models [14]. This selectivity distinguishes ezetimibe from bile acid sequestrants (which bind bile acids nonspecifically and affect multiple enterohepatic cycling processes) and from plant sterols and stanols (which compete with cholesterol for micellar solubilization and may affect fat-soluble vitamin absorption at high doses).

4.5 Effects on plant sterols

NPC1L1 also mediates the intestinal absorption of plant sterols (sitosterol, campesterol, stigmasterol). Ezetimibe reduces plant sterol absorption, which is the basis for its approved indication in homozygous sitosterolemia, a rare autosomal recessive disorder of plant sterol accumulation caused by loss-of-function mutations in the ABCG5/ABCG8 sterol efflux transporter [15].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Ezetimibe is rapidly absorbed from the gastrointestinal tract after oral administration of the 10 mg tablet. Peak plasma concentrations of total ezetimibe (parent plus glucuronide conjugate) are reached within 1 to 2 hours. Absolute bioavailability has not been precisely determined owing to the compound's low aqueous solubility, which precludes intravenous formulation for a definitive bioavailability study. The relative bioavailability is variable, with inter-subject coefficients of variation for AUC of 35 to 60 percent. Food does not significantly affect the extent of absorption, although high-fat meals modestly increase the rate of absorption [12].

5.2 Distribution

Ezetimibe is highly bound to plasma proteins (greater than 99.7 percent for the parent compound and greater than 88 percent for the glucuronide conjugate). Volume of distribution has not been precisely determined in humans. The compound localizes predominantly to the small intestinal wall and the liver, consistent with its site of action at the NPC1L1 transporter. The small intestinal concentration of ezetimibe and its glucuronide is maintained by enterohepatic recirculation through biliary excretion and reabsorption [12].

5.3 Metabolism

The principal metabolic transformation of ezetimibe is glucuronidation at the 4-hydroxyphenyl group by uridine 5'-diphosphate-glucuronosyltransferase (UGT) isoenzymes. The primary UGT isoforms responsible are UGT1A1, UGT1A3, and UGT2B15 in the intestinal wall and the liver [12, 16]. Glucuronidation occurs rapidly during first-pass metabolism, and the glucuronide conjugate (ezetimibe-glucuronide) constitutes 80 to 90 percent of circulating drug, with parent ezetimibe accounting for 10 to 20 percent. The glucuronide conjugate retains full pharmacological activity at NPC1L1, a property that is central to the sustained efficacy of the compound.

Cytochrome P450 metabolism is minimal. Ezetimibe is not a substrate, inhibitor, or inducer of the major CYP isoforms (CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4) at clinically relevant concentrations [12]. This property distinguishes ezetimibe from the statin class and confers a favorable drug-drug interaction profile.

Both ezetimibe and ezetimibe-glucuronide undergo enterohepatic recirculation: the glucuronide conjugate is excreted into bile, hydrolyzed in the intestinal lumen (by bacterial and intestinal beta-glucuronidases) to regenerate parent ezetimibe, which is then re-glucuronidated and reabsorbed. This recycling produces multiple plasma concentration peaks and extends the effective half-life to approximately 22 hours, supporting once-daily dosing [12].

5.4 Elimination

The terminal elimination half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours. Approximately 78 percent of the administered dose is recovered in feces, predominantly as parent ezetimibe (reflecting both unabsorbed drug and biliary excretion followed by intestinal deconjugation). Approximately 11 percent of the dose is recovered in urine, predominantly as ezetimibe-glucuronide. Renal clearance contributes minimally to overall elimination [12].

5.5 Routes of administration

Ezetimibe is administered exclusively by the oral route. The standard dose is 10 mg once daily, taken with or without food. No parenteral or topical formulations are commercially available. The compound is available as a single-entity 10 mg tablet (Zetia/Ezetrol) and in fixed-dose combination tablets with simvastatin (Vytorin/Inegy: 10 mg ezetimibe with 10, 20, 40, or 80 mg simvastatin), with atorvastatin (Atozet/Liptruzet), and with rosuvastatin (Rosuzet). A fixed-dose combination with bempedoic acid (Nexlizet/Nustendi: 180 mg bempedoic acid with 10 mg ezetimibe) was approved in 2020 [17].

5.6 Special populations

Mild hepatic impairment (Child-Pugh A) does not require dose adjustment; moderate to severe hepatic impairment (Child-Pugh B and C) results in substantially increased ezetimibe exposure (approximately 4-fold increase in AUC), and use is not recommended in these populations. Renal impairment does not require dose ad-

justment. No dose adjustment is recommended for elderly patients. Pediatric use (ages 10 years and older) at the standard 10 mg dose is approved in some jurisdictions for heterozygous familial hypercholesterolemia in combination with a statin. Ezetimibe is contraindicated during pregnancy when combined with a statin and is not recommended as monotherapy during pregnancy or lactation owing to insufficient human safety data.

6. Preclinical Pharmacology

6.1 Cholesterol absorption inhibition in rodent models

Ezetimibe was first characterized as a cholesterol absorption inhibitor in the cholesterol-fed hamster model, the standard preclinical screen for the azetidinone series at Schering-Plough [4]. At oral doses of 0.01 to 10 mg/kg, ezetimibe produced dose-dependent inhibition of intestinal cholesterol absorption, with near-complete inhibition (greater than 90 percent) at doses above 3 mg/kg. The compound selectively inhibited cholesterol absorption without affecting the absorption of triglycerides, fatty acids, or fat-soluble vitamins, establishing the selectivity profile that was subsequently confirmed in clinical studies [14].

In mice, ezetimibe at doses of 1 to 10 mg/kg reduced plasma cholesterol levels in animals fed both cholesterol-supplemented and cholesterol-free diets, indicating inhibition of both dietary and biliary cholesterol absorption. The activity in the cholesterol-free diet confirmed that the compound targets biliary cholesterol reabsorption through the enterohepatic circulation, consistent with the NPC1L1 localization on enterocyte brush border membranes [14].

6.2 Atherosclerosis models

Davis et al. (2001) demonstrated that ezetimibe inhibited the development of atherosclerosis in apolipoprotein E knockout (ApoE^{-/-}) mice, the standard genetic model of accelerated atherogenesis [18]. Cholesterol absorption was inhibited by greater than 90 percent at doses of ezetimibe above 3 mg/kg in ApoE^{-/-} mice. Plasma cholesterol was reduced from 964 to 374 mg/dL in mice fed a Western diet, from 726 to 231 mg/dL in mice on a low-fat diet, and from 516 to 178 mg/dL in mice receiving a cholesterol-free diet. Aortic atherosclerotic lesion area was reduced in proportion to the cholesterol lowering across all dietary conditions, demonstrating that the anti-atherosclerotic activity was attributable to the systemic cholesterol reduction rather than to a direct vascular mechanism.

Subsequent studies in ApoE-deficient mice demonstrated that ezetimibe reduced aortic plaque area, macrophage infiltration, and expression of inflammatory markers within atherosclerotic lesions, suggesting plaque-stabilizing effects consistent

with reduced delivery of atherogenic lipoprotein cholesterol to the vessel wall [19]. Studies in SR-BI/ApoE double knockout mice demonstrated that inhibition of intestinal cholesterol absorption by ezetimibe extended lifespan in this accelerated atherosclerosis model [20].

6.3 Primate studies

In rhesus monkeys fed a cholesterol-supplemented diet (375 mg/day), ezetimibe at 0.1 mg/kg completely prevented the diet-induced doubling of plasma cholesterol [21]. LDL cholesterol was reduced dose-dependently, while HDL cholesterol and plasma triglycerides were unchanged. The primate data confirmed the species-translatable pharmacology and supported the dose selection for human clinical development.

6.4 NPC1L1 knockout studies

Altmann et al. (2004) generated NPC1L1 knockout mice and demonstrated that these animals exhibited a 69 percent reduction in intestinal cholesterol absorption compared to wild-type littermates, closely phenocopying the effect of ezetimibe [5]. NPC1L1 knockout mice were resistant to diet-induced hypercholesterolemia and showed no additional cholesterol-lowering response to ezetimibe, confirming NPC1L1 as the molecular target. The knockout studies also demonstrated that NPC1L1 is required for efficient absorption of plant sterols, providing the molecular basis for the sitosterolemia indication.

7. Clinical Evidence Base

7.1 Primary hypercholesterolemia: monotherapy

Multiple Phase 3 trials have established the efficacy of ezetimibe 10 mg once daily as monotherapy in primary hypercholesterolemia. In a pooled analysis of registration trials, ezetimibe produced mean LDL-C reductions of 18.5 percent, total cholesterol reductions of 13 percent, triglyceride reductions of 5 percent, and HDL-C increases of 1.5 percent compared to placebo [7]. The LDL-C lowering effect is consistent across patient subgroups defined by age, sex, race, baseline LDL-C level, and cardiovascular risk category. Apolipoprotein B reductions of 15 to 17 percent and non-HDL-C reductions of approximately 18 percent were also observed.

7.2 Combination with statins

The addition of ezetimibe 10 mg to ongoing statin therapy at any dose produces an incremental LDL-C reduction of approximately 23 to 24 percent beyond the statin effect [8]. In a trial of ezetimibe added to simvastatin 10 to 80 mg, the combination of ezetimibe 10 mg plus simvastatin 10 mg produced LDL-C reduction equivalent to simvastatin 80 mg alone, demonstrating that ezetimibe can achieve intensive LDL-C targets without requiring high-dose statin therapy and its associated myopathy risk [8]. Davidson et al. (2002) confirmed these findings in a trial of ezetimibe coadministered with simvastatin, demonstrating LDL-C reductions of 45 to 60 percent with the combination across statin dose levels [22]. The additive mechanism (absorption inhibition plus synthesis inhibition) produces a complementary pharmacological profile that is the basis for the fixed-dose combination products and for the guideline recommendation of ezetimibe as a first-line add-on agent.

7.3 IMPROVE-IT: cardiovascular outcomes

The IMPROVE-IT trial (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) is the landmark cardiovascular outcomes study for ezetimibe [1]. The trial randomized 18,144 patients who had been hospitalized for an acute

coronary syndrome within the preceding 10 days to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo, with follow-up for a median of six years.

The primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, unstable angina requiring hospitalization, coronary revascularization occurring 30 or more days after randomization, or non-fatal stroke) occurred in 32.7 percent of patients in the ezetimibe-simvastatin group versus 34.7 percent in the simvastatin-alone group (absolute risk reduction 2.0 percentage points; hazard ratio 0.936; 95 percent confidence interval 0.89 to 0.99; $p = 0.016$). The median LDL-C achieved in the ezetimibe-simvastatin group was 53.7 mg/dL compared to 69.5 mg/dL in the simvastatin-alone group.

The benefit was driven predominantly by reductions in myocardial infarction (hazard ratio 0.87; $p = 0.002$) and ischemic stroke (hazard ratio 0.79; $p = 0.008$), with no significant effect on cardiovascular mortality alone. Prespecified subgroup analyses demonstrated particular benefit in patients with diabetes mellitus (absolute risk reduction 5.5 percentage points) and in patients at higher baseline cardiovascular risk as determined by biomarker levels [23]. The safety profile was equivalent between groups, with no excess myopathy, hepatotoxicity, cancer, or other serious adverse events.

Analysis of total cardiovascular events (including recurrent events) demonstrated that the reduction with ezetimibe/simvastatin more than doubled the number of events prevented compared to examining only the first event, underscoring the clinical significance of the combination in high-risk post-ACS patients [24].

The IMPROVE-IT trial is significant beyond the ezetimibe-specific context because it provided the first randomized evidence that LDL-C lowering by a non-statin mechanism produces cardiovascular event reduction proportional to the LDL-C decrease, consistent with the Cholesterol Treatment Trialists' Collaboration meta-regression and supporting the principle that the clinical benefit of LDL-C lowering is determined by the magnitude of reduction, not the mechanism.

7.4 SHARP: chronic kidney disease

The Study of Heart and Renal Protection (SHARP) randomized 9,270 patients with chronic kidney disease (approximately one-third on dialysis) to simvastatin 20 mg plus ezetimibe 10 mg versus placebo [2]. At a median follow-up of 4.9 years, the pri-

mary outcome of first major atherosclerotic event (non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or arterial revascularization) occurred in 11.3 percent of the treatment group versus 13.4 percent of the placebo group (rate ratio 0.83, 95 percent confidence interval 0.74 to 0.94, $p = 0.0021$). The benefit was driven by reductions in ischemic stroke and arterial revascularization procedures. No excess adverse events were observed in the treatment group [2].

The SHARP trial established the safety and efficacy of lipid lowering with simvastatin-ezetimibe in chronic kidney disease, a population in which prior statin-only trials (4D, AURORA) had failed to demonstrate cardiovascular benefit in dialysis patients.

7.5 EWTOPIA 75: elderly patients

The EWTOPIA 75 trial (Ouchi et al. 2019) randomized 3,796 Japanese patients aged 75 years or older with elevated LDL-C but without established cardiovascular disease to ezetimibe 10 mg monotherapy versus dietary counseling alone [25]. The primary composite endpoint of sudden cardiac death, myocardial infarction, coronary revascularization, or stroke was significantly reduced in the ezetimibe group (hazard ratio 0.66, 95 percent confidence interval 0.50 to 0.86, $p = 0.002$). This trial provided evidence for the cardiovascular benefit of ezetimibe as monotherapy in primary prevention in elderly patients, a population in which statin therapy is often limited by comorbidities, polypharmacy, or adverse effects.

7.6 Familial hypercholesterolemia

Ezetimibe is approved for use in combination with a statin in homozygous familial hypercholesterolemia. In clinical trials, the addition of ezetimibe to statin therapy in patients with homozygous familial hypercholesterolemia produced an additional 15 to 20 percent LDL-C reduction beyond statin monotherapy, a clinically meaningful decrement in a population with severely limited treatment options [26].

7.7 Sitosterolemia

Ezetimibe is the standard pharmacotherapy for homozygous sitosterolemia, a rare autosomal recessive disorder characterized by hyperabsorption and impaired biliary excretion of plant sterols due to loss-of-function mutations in the ABCG5/ABCG8 sterol transporter complex. In clinical trials, ezetimibe 10 mg daily

reduced plasma sitosterol levels by approximately 21 percent and plasma campesterol levels by approximately 24 percent [15]. The NPC1L1 inhibition reduces intestinal plant sterol absorption, complementing the deficient biliary excretion.

8. Sourcing and Quality Verification

Pharmaceutical-grade ezetimibe is widely available as 10 mg tablets (Zetia, Ezetrol, and multiple generic formulations) from branded and generic pharmaceutical manufacturers in essentially all regulated jurisdictions. Following patent expiration, generic pricing has reduced substantially, with tablets available at approximately \$0.10 to \$0.50 per unit in most markets.

Research-grade ezetimibe is supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Cayman Chemical, Selleckchem, MedChemExpress, MedKoo Biosciences, Tocris, Santa Cruz Biotechnology, and others) at greater than 98 percent purity by HPLC. Supply is available in milligram to gram quantities as the free base crystalline powder. Pricing is moderate, in the range of \$30 to \$150 per gram of research-grade material.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (410.16 for the protonated free base $[M+H]^+$)
- Chiral HPLC confirmation of enantiomeric purity (greater than 99 percent enantiomeric excess of the (3R,4S,3'S) configuration)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) for structural confirmation
- Karl Fischer analysis for residual water content
- Residual solvent analysis by gas chromatography

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade ezetimibe market is well established owing to the compound's widespread use in lipid metabolism research, and counterfeit material is uncommon. Lot-to-lot variability in polymorphic form and crystallinity may affect dissolution characteristics in cell-based and in vivo studies; investigators should characterize dissolution behavior if bioavailability-dependent endpoints are being measured.

9. Reconstitution and Handling

Ezetimibe free base has very low aqueous solubility (less than 0.01 mg/mL at pH 7.0). For in vitro research applications, the compound is typically dissolved in dimethyl sulfoxide (DMSO) at concentrations of 10 to 100 mM to prepare stock solutions, then diluted into aqueous media at working concentrations. The final DMSO concentration should be maintained below 0.1 to 0.5 percent (volume/volume) to avoid solvent effects on cellular assays. Ethanol and dimethylformamide are alternative solvents for preparing stock solutions at concentrations up to approximately 10 mg/mL.

For in vivo rodent studies, ezetimibe is commonly administered as an oral suspension in 0.5 percent methylcellulose, 0.5 percent carboxymethylcellulose, or polyethylene glycol 400. The suspension should be freshly prepared or stored at 2 to 8 degrees Celsius and used within 7 days. Sonication or gentle warming may be required to achieve homogeneous suspension of the poorly soluble powder. For alternative formulations, solutions in polyethylene glycol 400 or in mixtures of Tween 80 and saline have been used in published preclinical studies. Dietary admixture at calculated concentrations in powdered chow is an alternative administration method for chronic rodent studies.

Storage of the solid compound should be at room temperature (15 to 25 degrees Celsius) in a dry environment protected from moisture. For long-term storage, 0 to 4 degrees Celsius or minus 20 degrees Celsius is recommended by most suppliers. The compound is stable under standard pharmaceutical storage conditions; no special atmospheric (inert gas) requirements apply. DMSO stock solutions should be stored at minus 20 degrees Celsius and are stable for at least 6 months; repeated freeze-thaw cycles should be minimized. Light protection is not required for routine storage but is reasonable practice for long-term archival of reference standards.

For clinical-research formulations, the commercially available 10 mg tablets are the standard source material. Tablets may be crushed and suspended for nasogastric tube administration in clinical studies where swallowing is not feasible, although bioavailability characterization of the crushed formulation should be confirmed.

10. Stack Interactions and Combinations

Ezetimibe has a favorable drug-drug interaction profile owing to its non-CYP450 metabolism. The principal interactions are pharmacodynamic (additive or complementary lipid-lowering mechanisms) rather than pharmacokinetic. Investigators conducting research with ezetimibe in combination regimens should consider the following:

Statins: The combination of ezetimibe with any statin produces additive LDL-C lowering (approximately 23 to 24 percent incremental reduction) through complementary mechanisms (absorption inhibition plus synthesis inhibition) [8]. No clinically significant pharmacokinetic interactions exist between ezetimibe and any currently marketed statin. The combination is the most extensively studied and clinically validated use of ezetimibe, with outcomes evidence from IMPROVE-IT and SHARP.

Fibrates: Gemfibrozil increases ezetimibe exposure by approximately 1.7-fold through inhibition of glucuronidation. Fenofibrate increases ezetimibe exposure by approximately 1.5-fold. The clinical significance of these increases is uncertain, but the combination of ezetimibe with gemfibrozil is not recommended in the US prescribing label owing to limited safety data and the potential for increased cholelithiasis risk [12]. The ezetimibe-fenofibrate combination has been used in clinical practice for mixed dyslipidemia.

Bile acid sequestrants: Cholestyramine decreases the AUC of total ezetimibe by approximately 55 percent when administered concomitantly, through binding of ezetimibe in the intestinal lumen [12]. The interaction can be managed by administering ezetimibe at least 2 hours before or at least 4 hours after the bile acid sequestrant. Colesevelam produces a smaller effect on ezetimibe exposure.

Cyclosporine: Cyclosporine increases ezetimibe exposure by approximately 3.4 to 12-fold, depending on the study population and the severity of renal impairment. The interaction is clinically significant, and concurrent use requires careful monitoring [12].

PCSK9 inhibitors: No pharmacokinetic interactions exist between ezetimibe and PCSK9 inhibitors (evolocumab, alirocumab) or inclisiran. The pharmacodynamic interaction is additive: ezetimibe reduces intestinal cholesterol absorption, PCSK9 inhibitors increase hepatic LDL receptor density, and the combination with a statin produces maximal LDL-C lowering (reductions of 75 to 85 percent from baseline are achievable with triple therapy). This combination represents the intensive end of guideline-directed lipid management [27].

Bempedoic acid: The fixed-dose combination of bempedoic acid 180 mg with ezetimibe 10 mg (Nexlizet/Nustendi) is approved for clinical use. The combination produces approximately 38 percent LDL-C reduction, greater than either agent alone [17]. No significant pharmacokinetic interaction exists between the two compounds.

Warfarin: Ezetimibe does not significantly affect the pharmacokinetics or pharmacodynamics of warfarin in controlled studies. However, postmarketing reports have described changes in International Normalized Ratio (INR) when ezetimibe is started or discontinued in patients receiving warfarin. Monitoring is recommended during initiation or discontinuation [12].

Other agents: Ezetimibe does not significantly interact with oral contraceptives, digoxin, glipizide, or commonly used antihypertensive agents. The absence of CYP-mediated metabolism limits the interaction potential with the large number of drugs metabolized by CYP3A4, CYP2C9, and CYP2D6.

11. Adverse Events and Safety

11.1 Common adverse events

The adverse-event profile of ezetimibe as monotherapy is similar to placebo in controlled clinical trials. The most frequently reported events include:

- Upper respiratory tract infection (4.3 percent versus 2.5 percent placebo)
- Diarrhea (4.1 percent versus 3.7 percent placebo)
- Arthralgia (3.0 percent versus 2.2 percent placebo)
- Sinusitis (2.8 percent versus 2.2 percent placebo)
- Pain in extremity (2.7 percent versus 2.5 percent placebo)
- Fatigue (2.4 percent versus 1.5 percent placebo)

These rates reflect pooled data from the pivotal clinical trial program. The frequencies are modest and the differences from placebo are small, supporting the characterization of ezetimibe as a well-tolerated compound [7].

11.2 Hepatic effects

Ezetimibe monotherapy is associated with a low rate of hepatic transaminase elevation (ALT or AST greater than 3 times the upper limit of normal: 0.5 percent versus 0.3 percent placebo). When combined with a statin, the rate of transaminase elevation is modestly higher (1.3 percent for ezetimibe plus statin versus 0.4 percent for statin alone), reflecting the additive hepatic pharmacology rather than a specific hepatotoxic mechanism [12]. Rare cases of cholestatic hepatitis, autoimmune hepatitis, and vanishing bile duct syndrome have been reported in postmarketing surveillance, with an estimated frequency of less than 1 in 10,000 treated patients [28]. Liver function monitoring is recommended at baseline and during concurrent statin therapy, consistent with statin prescribing guidelines.

11.3 Musculoskeletal effects

Ezetimibe monotherapy has not been associated with increased myopathy risk in controlled trials. When combined with statins, the myopathy rate is consistent with the background statin-associated rate and is not significantly elevated by the addition of ezetimibe. The IMPROVE-IT trial reported no excess myopathy or rhabdomyolysis in the ezetimibe-simvastatin group compared to the simvastatin-alone group over six years of follow-up [1]. Postmarketing disproportionality analyses of the FDA Adverse Event Reporting System have identified a signal for rhabdomyolysis with ezetimibe, particularly in combination with simvastatin or atorvastatin, though the absolute risk remains very low and causality has not been established in controlled studies [29]. Patients should be monitored for myalgia or muscle weakness, particularly when ezetimibe is combined with high-dose statin therapy.

11.4 Cancer safety

An early meta-analysis (Peto et al. 2008) raised a hypothesis of increased cancer incidence with ezetimibe plus statin versus statin alone, which generated substantial clinical concern [30]. This hypothesis was subsequently refuted by the individual trial data from IMPROVE-IT and SHARP, both of which showed no excess cancer incidence or cancer mortality with ezetimibe treatment over extended follow-up (six years in IMPROVE-IT, 4.9 years in SHARP) [1, 2]. A subsequent Cholesterol Treatment Trialists' Collaboration meta-analysis including all available data confirmed no association between ezetimibe use and cancer risk. The FDA and EMA have both concluded that the available evidence does not support a causal relationship.

11.5 Gallbladder effects

Ezetimibe does not increase gallstone formation risk as monotherapy in controlled trials. The increase in biliary cholesterol excretion that results from cholesterol absorption inhibition has a theoretical basis for cholesterol gallstone formation in susceptible individuals. The IMPROVE-IT trial reported no excess gallbladder adverse events with ezetimibe [1].

11.6 Pregnancy and lactation

Ezetimibe is classified as contraindicated during pregnancy when combined with a statin. As monotherapy, animal reproduction studies have not demonstrated teratogenicity at doses producing exposures up to 10-fold human exposure, but human pregnancy data are insufficient to establish safety. Use during pregnancy is not recommended. Ezetimibe is excreted in rat milk; human lactation data are limited, and use during breastfeeding is not recommended.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five non-statin lipid-lowering agents against ezetimibe, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal alternatives to ezetimibe in the non-statin lipid management space, with priority on agents with cardiovascular outcomes data or with substantial clinical positioning as statin add-on therapy.

12.1 Bempedoic acid (Nexletol, ETC-1002)

Mechanism: ATP citrate lyase (ACL) inhibitor. Bempedoic acid is a prodrug that is activated by very-long-chain acyl-CoA synthetase 1 (ACSVL1) in the liver to form bempedoyl-CoA, which inhibits ACL upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. Because ACSVL1 is not expressed in skeletal muscle, bempedoic acid does not produce statin-like muscle effects [31].

Novelty: High. The ACL inhibition mechanism is distinct from all previously developed lipid-lowering classes and represents a novel point of intervention in the cholesterol synthesis pathway.

Effect size: Bempedoic acid monotherapy reduces LDL-C by approximately 18 to 25 percent. In combination with ezetimibe, LDL-C reductions of approximately 38 percent are achieved. The CLEAR Outcomes trial (Nissen et al. 2023) demonstrated a 13 percent relative reduction in the primary composite cardiovascular endpoint (hazard ratio 0.87, 95 percent confidence interval 0.79 to 0.96, $p = 0.004$) in 13,970 statin-intolerant patients, the first cardiovascular outcomes evidence for this mechanism [32].

Promising potential: High. The compound is approved and clinically deployed. The fixed-dose combination with ezetimibe (Nexlizet) extends the clinical utility. Particular value exists for statin-intolerant patients in whom bempedoic acid provides an oral alternative with demonstrated outcomes benefit.

Side-effect profile: Generally well tolerated. The principal adverse events are hyperuricemia (approximately 2 percent incidence, occasionally precipitating gout), tendon rupture (rare but identified in clinical trials and postmarketing), and elevated creatinine (modest, non-progressive). The absence of muscle toxicity is a significant differentiator from statins [31, 32].

Overall validation: High. Phase 3 cardiovascular outcomes data (CLEAR Outcomes) plus regulatory approval plus a favorable safety profile in the statin-intolerant population.

Comparison to ezetimibe: Bempedoic acid and ezetimibe have comparable LDL-C lowering efficacy as monotherapy (18 to 25 percent versus 15 to 22 percent). Ezetimibe has longer clinical experience, lower cost (generic), and broader outcomes data (IMPROVE-IT, SHARP, EWTOPIA 75). Bempedoic acid has the advantage of a novel mechanism and outcomes data in the statin-intolerant population. The fixed-dose combination of both agents represents a high-value oral regimen for patients who cannot tolerate statins.

12.2 Evolocumab (Repatha)

Mechanism: Fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding and neutralizing circulating PCSK9, evolocumab prevents PCSK9-mediated degradation of hepatic LDL receptors, increasing receptor density and LDL particle clearance from plasma [33].

Novelty: High at the time of approval (2015). The PCSK9 inhibition mechanism was a novel therapeutic target validated through human genetic studies showing that loss-of-function PCSK9 mutations confer lifelong low LDL-C and reduced cardiovascular risk.

Effect size: Evolocumab reduces LDL-C by approximately 55 to 60 percent when added to statin therapy, substantially greater than ezetimibe. The FOURIER trial (Sabatine et al. 2017) in 27,564 patients with established atherosclerotic cardiovascular disease demonstrated a 15 percent relative reduction in the primary composite cardiovascular endpoint (hazard ratio 0.85, $p < 0.001$) over a median follow-up of 2.2 years [33].

Promising potential: High. Regulatory approval in more than 60 jurisdictions. Ongoing studies in additional populations. The 10-year open-label extension data (FOURIER-OLE) confirm sustained efficacy and safety.

Side-effect profile: Generally well tolerated. The principal adverse events are injection-site reactions (3 to 5 percent), nasopharyngitis, and upper respiratory infections. Neurocognitive effects have been monitored extensively; the EBBINGHAUS cognitive sub-study of FOURIER showed no difference between evolocumab and placebo on cognitive endpoints [33].

Overall validation: Very high. Phase 3 cardiovascular outcomes data (FOURIER), regulatory approval, extensive real-world evidence, and long-term follow-up safety data.

Comparison to ezetimibe: Evolocumab produces substantially greater LDL-C lowering than ezetimibe (55 to 60 percent versus 18 percent) and has a larger relative risk reduction in cardiovascular events. However, evolocumab requires subcutaneous injection (every 2 or 4 weeks), has substantially higher cost, and is typically reserved for patients who have not achieved LDL-C goals on maximally tolerated statin plus ezetimibe. Ezetimibe has the advantages of oral administration, generic pricing, and established positioning as the standard first-line add-on to statin therapy.

12.3 Alirocumab (Praluent)

Mechanism: Fully human monoclonal antibody against PCSK9, mechanistically identical to evolocumab [34].

Novelty: Shared with the PCSK9 inhibitor class. Alirocumab was developed by Regeneron Pharmaceuticals and Sanofi in parallel with evolocumab.

Effect size: LDL-C reduction of approximately 50 to 60 percent when added to statin therapy, comparable to evolocumab. The ODYSSEY OUTCOMES trial (Schwartz et al. 2018) in 18,924 patients with recent acute coronary syndrome demonstrated a 15 percent relative reduction in the primary composite cardiovascular endpoint (hazard ratio 0.85, $p < 0.001$) [34]. A prespecified analysis showed a significant reduction in all-cause mortality (hazard ratio 0.85, $p = 0.026$) in a subgroup with baseline LDL-C greater than or equal to 100 mg/dL.

Promising potential: High. Regulatory approval in multiple jurisdictions. The all-cause mortality signal in ODYSSEY OUTCOMES is a distinguishing finding not observed in FOURIER.

Side-effect profile: Similar to evolocumab. Injection-site reactions, nasopharyngitis, and upper respiratory infections. No excess neurocognitive adverse events [34].

Overall validation: Very high. Phase 3 cardiovascular outcomes data (ODYSSEY OUTCOMES), regulatory approval, and extensive clinical experience.

Comparison to ezetimibe: The comparison parallels that of evolocumab versus ezetimibe. Alirocumab offers substantially greater LDL-C lowering at the cost of injectable administration and higher expense. In clinical practice, ezetimibe is used before PCSK9 inhibitors in the treatment escalation algorithm, and the two are often combined for maximal LDL-C reduction.

12.4 Inclisiran (Leqvio)

Mechanism: Small interfering RNA (siRNA) targeting hepatic PCSK9 messenger RNA. Inclisiran is a synthetic double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc) for hepatocyte-targeted delivery. Following uptake by the asialoglycoprotein receptor, inclisiran engages the RNA-induced silencing complex (RISC) to degrade PCSK9 mRNA, suppressing intracellular PCSK9 synthesis and reducing circulating PCSK9 protein [35].

Novelty: Very high. Inclisiran is the first siRNA therapeutic approved for cardiovascular disease and represents a fundamentally novel mechanism (intracellular PCSK9 synthesis inhibition versus extracellular PCSK9 neutralization by monoclonal antibodies).

Effect size: Inclisiran reduces LDL-C by approximately 50 percent when added to maximally tolerated statin therapy. The dosing schedule (subcutaneous injection at day 1, day 90, and every 6 months thereafter) provides sustained LDL-C lowering with twice-yearly administration [35]. Cardiovascular outcomes data from the ORION-4 trial (approximately 15,000 patients) are expected but have not yet been published at the time of this monograph revision.

Promising potential: High. Regulatory approval in the European Union (2020), the United States (2021), and other jurisdictions. The twice-yearly dosing schedule addresses adherence challenges associated with daily oral medications and monthly/biweekly injections.

Side-effect profile: The principal adverse events are injection-site reactions (8 to 9 percent, mild and transient), nasopharyngitis, and arthralgia. No significant hepatotoxicity, myopathy, or neurocognitive effects have been observed in Phase 3 trials [35].

Overall validation: Moderate to high. LDL-C lowering efficacy is well established, but cardiovascular outcomes evidence from a dedicated trial is pending. The twice-yearly dosing is a significant practical advantage.

Comparison to ezetimibe: Inclisiran produces substantially greater LDL-C lowering (50 percent versus 18 percent) with the convenience of twice-yearly injection versus daily oral dosing. Cost is substantially higher. Ezetimibe retains advantages of oral administration, generic pricing, and established outcomes data. In practice, inclisiran is positioned after statin plus ezetimibe optimization for patients who remain above LDL-C goals.

12.5 Colesevelam (Welchol)

Mechanism: Bile acid sequestrant. Colesevelam is a non-absorbed hydrophilic polymer that binds bile acids in the intestinal lumen, preventing enterohepatic recirculation and increasing hepatic bile acid synthesis from cholesterol, thereby depleting hepatic cholesterol and upregulating LDL receptor expression [36].

Novelty: Low. Bile acid sequestrants are among the oldest lipid-lowering drug classes, with cholestyramine first approved in the 1970s. Colesevelam is a second-generation sequestrant with improved tolerability compared to cholestyramine and colestipol.

Effect size: Colesevelam reduces LDL-C by approximately 10 to 18 percent as monotherapy and provides an incremental 10 to 16 percent reduction when added to statin therapy [36]. The Lipid Research Clinics Coronary Primary Prevention Trial (1984) demonstrated that cholestyramine (the first-generation bile acid sequestrant) reduced coronary events in a pre-statin era trial, but no dedicated cardiovascular outcomes trial has been conducted with colesevelam.

Promising potential: Low to moderate. The compound is approved and clinically available but is infrequently prescribed owing to gastrointestinal adverse effects, inconvenient dosing (multiple large tablets or suspension packets daily), and the availability of better-tolerated alternatives.

Side-effect profile: The principal adverse events are gastrointestinal: constipation (11 percent), dyspepsia (8 percent), nausea (4 percent), and abdominal bloating. Bile acid sequestrants can increase triglycerides and should be used with caution in patients with hypertriglyceridemia. Drug interactions are significant: bile acid sequestrants bind many concomitant oral medications and reduce their absorption, requiring staggered dosing [36].

Overall validation: Low to moderate. The bile acid sequestrant class has historical outcomes evidence from the pre-statin era (LRC-CPPT) but no modern outcomes trial with colesevelam. Clinical use has declined substantially with the availability of ezetimibe and PCSK9 inhibitors.

Comparison to ezetimibe: Ezetimibe is superior to colesevelam on essentially all practical measures: greater and more consistent LDL-C lowering, markedly better tolerability, fewer drug interactions, once-daily tablet dosing versus multiple daily tablets, and cardiovascular outcomes evidence. Colesevelam has the advantage of an additional indication for glycemic control in type 2 diabetes (modest HbA1c reduction) and may be used in patients who cannot tolerate ezetimibe, though this scenario is uncommon.

12.6 Comparator summary

The five compounds occupy distinct positions in the non-statin lipid management landscape. **Bempedoic acid** is the most directly comparable to ezetimibe in terms of LDL-C lowering magnitude and oral administration and has established cardiovascular outcomes evidence (CLEAR Outcomes); the fixed-dose combination with ezetimibe represents a valuable oral regimen for statin-intolerant patients. **Evolocumab** and **alirocumab** produce substantially greater LDL-C lowering with robust cardiovascular outcomes data but require injectable administration and have higher cost; they are positioned after ezetimibe in the treatment escalation pathway. **Inclisiran** offers the novel siRNA mechanism with twice-yearly dosing convenience but awaits dedicated cardiovascular outcomes evidence. **Colesevelam** is the oldest mechanism with the weakest evidence base and tolerability profile and has been largely superseded by ezetimibe in clinical practice.

Ezetimibe occupies a central position in this comparator landscape: it is the most widely prescribed non-statin lipid-lowering agent, the first-line add-on to statin therapy in all major clinical guidelines, the least expensive option (generic), and the compound with the broadest cardiovascular outcomes evidence across

multiple clinical populations (post-acute coronary syndrome, chronic kidney disease, elderly primary prevention). Its LDL-C lowering effect is modest compared to PCSK9 inhibitors and inclisiran but is sufficient for a substantial proportion of patients who need incremental reduction beyond statin monotherapy. The complementary mechanism of action supports combination with all other classes, and ezetimibe is routinely used as a component of multi-drug lipid-lowering regimens that include statins, PCSK9 inhibitors, and bempedoic acid.

13. References

1. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372(25):2387-2397.
2. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011;377(9784):2181-2192.
3. Clader JW. The discovery of ezetimibe: a view from outside the receptor. *J Med Chem*. 2004;47(1):1-9.
4. Rosenblum SB, Huynh T, Afonso A, et al. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. *J Med Chem*. 1998;41(6):973-980.
5. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. *Science*. 2004;303(5661):1201-1204.
6. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). *Proc Natl Acad Sci USA*. 2005;102(23):8132-8137.
7. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. *Eur Heart J*. 2003;24(8):729-741.
8. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. *Circulation*. 2003;107(19):2409-2415.
9. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med*. 2008;358(14):1431-1443.
10. Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. *Cell Metab*. 2008;7(6):508-519.

11. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. *J Clin Invest*. 2007;117(7):1968-1978.
12. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. *Clin Pharmacokinet*. 2005;44(5):467-494.
13. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation*. 2002;106(15):1943-1948.
14. Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH 48461. *J Pharmacol Exp Ther*. 1997;283(1):157-163.
15. Salen G, von Bergmann K, Lutjohann D, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. *Circulation*. 2004;109(8):966-971.
16. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). *Drug Metab Dispos*. 2004;32(3):314-320.
17. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol*. 2020;27(6):593-603.
18. Davis HR Jr, Compton DS, Hoos L, et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. *Arterioscler Thromb Vasc Biol*. 2001;21(12):2032-2038.
19. Nomura M, Ishii H, Kawakami A, et al. Vascular protective effects of ezetimibe in ApoE-deficient mice. *Atherosclerosis*. 2009;206(2):425-433.
20. Braun A, Yesilaltay A, Acton S, et al. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. *Atherosclerosis*. 2008;195(1):e31-e38.

21. Telford DE, Sutherland BG, Edwards JY, et al. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. *Eur J Pharmacol.* 2001;415(1):79-84.
22. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. *J Am Coll Cardiol.* 2002;40(12):2125-2134.
23. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT. *Circulation.* 2018;137(15):1571-1582.
24. Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. *J Am Coll Cardiol.* 2016;67(4):353-361.
25. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): a randomized, controlled trial. *Circulation.* 2019;140(12):992-1003.
26. Gagne C, Gaudet D, Bruckert E, et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation.* 2002;105(21):2469-2475.
27. Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. *Eur Heart J.* 2018;39(14):1172-1180.
28. Castellote J, Ariza J, Rota R, et al. Serious drug-induced liver disease secondary to ezetimibe. *World J Gastroenterol.* 2008;14(32):5098-5099.
29. Ezetimibe-associated rhabdomyolysis: a comprehensive assessment of the USFDA adverse event reporting system using disproportionality analysis, case reviews, and meta-analysis of randomized clinical trials. *Int J Clin Pharm.* 2024;46(5):1127-1136.
30. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. *N Engl J Med.* 2008;359(13):1357-1366.
31. Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. *Curr Atheroscler Rep.* 2016;18(10):61.

32. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388(15):1353-1364.
33. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376(18):1713-1722.
34. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379(22):2097-2107.
35. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med*. 2020;382(16):1507-1519.
36. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. *Atherosclerosis*. 2009;204(2):342-344.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Ezetimibe is approved by the United States Food and Drug Administration for the treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, homozygous sitosterolemia, and mixed hyperlipidemia. Investigators should consult their local regulatory authority and institutional review requirements before any research application.